Lactococcus garvieae bacteriophage Lac-GAP-3 and use thereof in inhibiting proliferation of Lactococcus garvieae bacteria
Inventors
Yoon, Seong Jun • JUN, Soo Youn • KWON, An Sung • Hwang, Soon Hye • Song, Hyun Min • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11351210-B2
Publication Date
2022-06-07
Expiration Date
Abstract
The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.
Core Innovation
The document describes a Siphoviridae bacteriophage designated Lac-GAP-3 (Accession number KCTC 12816BP), including a genome expressed by SEQ ID NO:1. The bacteriophage is characterized and used as an active ingredient in a composition for preventing and treating Lactococcus garvieae associated fish streptococcosis.
The document states that Lac-GAP-3 specifically kills Lactococcus garvieae, with killing demonstrated across 13/15 Lactococcus garvieae strains and no killing of several non-target bacteria. The document also reports in vitro growth inhibition of Lactococcus garvieae and related experimental observations supporting the use of the phage composition.
The document describes the prevention and treatment of Lactococcus garvieae infection in olive flounder using the composition containing Lac-GAP-3, reporting preventive efficacy and treatment efficacy through reductions in body darkening index (DC score). It also describes farming benefits based on use as a medicine bath agent (immersion agent) and as a feed additive, with effects reported as reductions in mortality.
Claims Coverage
The independent claim provides coverage for one core inventive concept, namely administering a specific phage-containing composition to non-human animals for treating Lactococcus garvieae infection, with a dependent refinement on the form of administration.
Phage-defined composition for non-human treatment of Lactococcus garvieae infection
Administering to an animal other than a human a composition including the Siphoviridae bacteriophage Lac-GAP-3 (Accession number KCTC 12816BP) which has an ability to specifically kill Lactococcus garvieae and which includes a genome expressed by SEQ ID NO:1 as an active ingredient.
Medicine bath agent or feed additive administration
Using the composition administered to the animal other than a human as a medicine bath agent or as a feed additive.
Overall, the claim coverage centers on non-human therapeutic use of a composition containing Siphoviridae bacteriophage Lac-GAP-3 with a genome expressed by SEQ ID NO:1 and specifically killing Lactococcus garvieae, with administration refined to a medicine bath agent or feed additive.
Stated Advantages
Specificity via specific killing of Lactococcus garvieae.
Fewer side effects compared with antibiotics.
Environmental friendliness compared with antibiotics.
Documented Applications
Preventing and treating Lactococcus garvieae infection (fish streptococcosis) in olive flounder.
Using the composition as a medicine bath agent (immersion agent).
Using the composition as a feed additive to provide farming benefits and reduce mortality.
Interested in licensing this patent?